Literature DB >> 19119142

FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells.

Evgeny V Berdyshev1, Irina Gorshkova, Anastasia Skobeleva, Robert Bittman, Xuequan Lu, Steven M Dudek, Tamara Mirzapoiazova, Joe G N Garcia, Viswanathan Natarajan.   

Abstract

Novel immunomodulatory molecule FTY720 is a synthetic analog of myriocin, but unlike myriocin FTY720 does not inhibit serine palmitoyltransferase. Although many of the effects of FTY720 are ascribed to its phosphorylation and subsequent sphingosine 1-phosphate (S1P)-like action through S1P(1,3-5) receptors, studies on modulation of intracellular balance of signaling sphingolipids by FTY720 are limited. In this study, we used stable isotope pulse labeling of human pulmonary artery endothelial cells with l-[U-(13)C, (15)N]serine as well as in vitro enzymatic assays and liquid chromatography-tandem mass spectrometry methodology to characterize FTY720 interference with sphingolipid de novo biosynthesis. In human pulmonary artery endothelial cells, FTY720 inhibited ceramide synthases, resulting in decreased cellular levels of dihydroceramides, ceramides, sphingosine, and S1P but increased levels of dihydrosphingosine and dihydrosphingosine 1-phosphate (DHS1P). The FTY720-induced modulation of sphingolipid de novo biosynthesis was similar to that of fumonisin B1, a classical inhibitor of ceramide synthases, but differed in the efficiency to inhibit biosynthesis of short-chain versus long-chain ceramides. In vitro kinetic studies revealed that FTY720 is a competitive inhibitor of ceramide synthase 2 toward dihydrosphingosine with an apparent K(i) of 2.15 microm. FTY720-induced up-regulation of DHS1P level was mediated by sphingosine kinase (SphK) 1, but not SphK2, as confirmed by experiments using SphK1/2 silencing with small interfering RNA. Our data demonstrate for the first time the ability of FTY720 to inhibit ceramide synthases and modulate the intracellular balance of signaling sphingolipids. These findings open a novel direction for therapeutic applications of FTY720 that focuses on inhibition of ceramide biosynthesis, ceramide-dependent signaling, and the up-regulation of DHS1P generation in cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19119142      PMCID: PMC2645812          DOI: 10.1074/jbc.M805186200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1.

Authors:  Gerald Schmid; Markus Guba; Ivan Ischenko; Armine Papyan; Mareile Joka; Sabine Schrepfer; Christiane J Bruns; Karl-Walter Jauch; Christopher Heeschen; Christian Graeb
Journal:  J Cell Biochem       Date:  2007-05-01       Impact factor: 4.429

Review 2.  FTY720: a most promising immunosuppressant modulating immune cell functions.

Authors:  Zhiren Zhang; Hermann J Schluesener
Journal:  Mini Rev Med Chem       Date:  2007-08       Impact factor: 3.862

Review 3.  Pharmacological modulation of sphingolipids and role in disease and cancer cell biology.

Authors:  Albert Morales; José C Fernandez-Checa
Journal:  Mini Rev Med Chem       Date:  2007-04       Impact factor: 3.862

4.  De novo C16- and C24-ceramide generation contributes to spontaneous neutrophil apoptosis.

Authors:  Grégory Seumois; Marianne Fillet; Laurent Gillet; Céline Faccinetto; Christophe Desmet; Cédric François; Benjamin Dewals; Cécile Oury; Alain Vanderplasschen; Pierre Lekeux; Fabrice Bureau
Journal:  J Leukoc Biol       Date:  2007-02-28       Impact factor: 4.962

5.  Elevation of sphingoid base 1-phosphate as a potential contributor to hepatotoxicity in fumonisin B1-exposed mice.

Authors:  Dong-Hyun Kim; Youn-Sun Lee; Yong-Moon Lee; Seikwan Oh; Yeo-Pyo Yun; Hwan-Soo Yoo
Journal:  Arch Pharm Res       Date:  2007-08       Impact factor: 4.946

6.  Ceramide-1-phosphate binds group IVA cytosolic phospholipase a2 via a novel site in the C2 domain.

Authors:  Robert V Stahelin; Preeti Subramanian; Mohsin Vora; Wonhwa Cho; Charles E Chalfant
Journal:  J Biol Chem       Date:  2007-04-30       Impact factor: 5.157

7.  Finding a way out: lymphocyte egress from lymphoid organs.

Authors:  Susan R Schwab; Jason G Cyster
Journal:  Nat Immunol       Date:  2007-12       Impact factor: 25.606

Review 8.  Principles of bioactive lipid signalling: lessons from sphingolipids.

Authors:  Yusuf A Hannun; Lina M Obeid
Journal:  Nat Rev Mol Cell Biol       Date:  2008-02       Impact factor: 94.444

9.  Dimethylsphingosine and FTY720 inhibit the SK1 form but activate the SK2 form of sphingosine kinase from rat heart.

Authors:  Donald A Vessey; Michael Kelley; Jianqing Zhang; Luyi Li; Rong Tao; Joel S Karliner
Journal:  J Biochem Mol Toxicol       Date:  2007       Impact factor: 3.642

10.  JNK3 signaling pathway activates ceramide synthase leading to mitochondrial dysfunction.

Authors:  Jin Yu; Sergei A Novgorodov; Daria Chudakova; Hong Zhu; Alicja Bielawska; Jacek Bielawski; Lina M Obeid; Mark S Kindy; Tatyana I Gudz
Journal:  J Biol Chem       Date:  2007-07-03       Impact factor: 5.157

View more
  72 in total

1.  A fluorescent assay for ceramide synthase activity.

Authors:  Hyun Joon Kim; Qiao Qiao; Hamish D Toop; Jonathan C Morris; Anthony S Don
Journal:  J Lipid Res       Date:  2012-06-01       Impact factor: 5.922

2.  Non-phosphorylated FTY720 induces apoptosis of human microglia by activating SREBP2.

Authors:  Takashi Yoshino; Hiroko Tabunoki; Shigeo Sugiyama; Keitaro Ishii; Seung U Kim; Jun-Ichi Satoh
Journal:  Cell Mol Neurobiol       Date:  2011-04-26       Impact factor: 5.046

3.  Sphingolipids--who's controlling who in disease?

Authors:  Claudine S Bonder; Stuart M Pitson
Journal:  Immunol Cell Biol       Date:  2015-08-04       Impact factor: 5.126

4.  FTY720/fingolimod increases NPC1 and NPC2 expression and reduces cholesterol and sphingolipid accumulation in Niemann-Pick type C mutant fibroblasts.

Authors:  Jason Newton; Nitai C Hait; Michael Maceyka; Alexandria Colaco; Melissa Maczis; Christopher A Wassif; Antony Cougnoux; Forbes D Porter; Sheldon Milstien; Nicholas Platt; Frances M Platt; Sarah Spiegel
Journal:  FASEB J       Date:  2017-01-12       Impact factor: 5.191

Review 5.  Targeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials.

Authors:  Thomas H Beckham; Saeed Elojeimy; Joseph C Cheng; Lorianne S Turner; Stanley R Hoffman; James S Norris; Xiang Liu
Journal:  Expert Opin Ther Targets       Date:  2010-05       Impact factor: 6.902

Review 6.  Beyond the cherry-red spot: Ocular manifestations of sphingolipid-mediated neurodegenerative and inflammatory disorders.

Authors:  Hui Chen; Annie Y Chan; Donald U Stone; Nawajes A Mandal
Journal:  Surv Ophthalmol       Date:  2013-09-05       Impact factor: 6.048

7.  Distinct generation, pharmacology, and distribution of sphingosine 1-phosphate and dihydrosphingosine 1-phosphate in human neural progenitor cells.

Authors:  Phillip Callihan; Nicholas C Zitomer; Michael V Stoeling; Perry C Kennedy; Kevin R Lynch; Ronald T Riley; Shelley B Hooks
Journal:  Neuropharmacology       Date:  2011-10-15       Impact factor: 5.250

8.  Differences and Similarities in TRAIL- and Tumor Necrosis Factor-Mediated Necroptotic Signaling in Cancer Cells.

Authors:  Justyna Sosna; Stephan Philipp; Johaiber Fuchslocher Chico; Carina Saggau; Jürgen Fritsch; Alexandra Föll; Johannes Plenge; Christoph Arenz; Thomas Pinkert; Holger Kalthoff; Anna Trauzold; Ingo Schmitz; Stefan Schütze; Dieter Adam
Journal:  Mol Cell Biol       Date:  2016-09-26       Impact factor: 4.272

9.  Stimulation of sphingosine 1-phosphate signaling as an alveolar cell survival strategy in emphysema.

Authors:  Khalil J Diab; Jeremy J Adamowicz; Krzysztof Kamocki; Natalia I Rush; Jana Garrison; Yuan Gu; Kelly S Schweitzer; Anastasia Skobeleva; Gangaraju Rajashekhar; Walter C Hubbard; Evgeny V Berdyshev; Irina Petrache
Journal:  Am J Respir Crit Care Med       Date:  2009-12-03       Impact factor: 21.405

10.  FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells.

Authors:  Francesca Tonelli; Keng Gat Lim; Carolyn Loveridge; Jaclyn Long; Stuart M Pitson; Gabor Tigyi; Robert Bittman; Susan Pyne; Nigel J Pyne
Journal:  Cell Signal       Date:  2010-06-04       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.